StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley sees a risk to Pfizer's (PFE) EPS guidance
January 6, 2023 10:08 AM
In a note to clients Friday, Morgan Stanley analyst Terence Flynn said the firm sees downside risk to Pfizer's (NYSE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot List
Next Articles
Pfizer (PFE) stock can outperform even in a 'trough COVID' scenario says Goldman Sachs
January 10, 2023 1:43 PM
Pfizer (PFE) Announces FDA Acceptance for Priority Review of sBLA for 20vPnC
January 6, 2023 6:47 AM
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
January 6, 2023 6:45 AM
Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM
Bank of America cuts Pfizer (PFE) on post-Covid uncertainties, upgrades Merck (MRK)
January 4, 2023 9:10 AM
